This site hosts a series of working papers exploring how advances in longevity medicine interact with inflation, asset performance, and long-duration economic planning. The motivation for this work is the observation that most economic frameworks treat human lifespan as fixed, even as biomedical research increasingly challenges that assumption.
These papers are exploratory in nature and are intended to surface boundary conditions between biology, economics, and finance rather than to offer predictions or investment advice. The focus is on conceptual frameworks and scenario analysis, with an emphasis on long-term implications at the individual and institutional levels.
I am a pharmacist and independent researcher with interests spanning longevity science, macroeconomics, and long-term financial planning.
